Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03939689 2025-10-14

ARROW

Phase 2 Completed

120 enrolled 21 charts

Genitourinary

Prostatic Neoplasms

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT05202301 2025-08-11

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Completed

13,779 enrolled

Genitourinary

Prostatic Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

NCT07104110 2025-08-05

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Phase 1/2 Not yet recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT06151418 2025-06-04

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

Completed

2,313 enrolled 5 charts

Genitourinary

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

Phase 3 Completed

688 enrolled 13 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04145375 2025-03-19

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Phase 1/2 Enrolling by invitation

40 enrolled

Genitourinary

Prostatic Neoplasms

NCT05075577 2025-02-28

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Phase 1/2 Terminated

77 enrolled

Genitourinary

Prostatic Neoplasms

NCT02918968 2024-12-09

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Phase 4 Completed

206 enrolled 16 charts

Genitourinary

Prostatic Neoplasms

NCT01288911 2024-12-06

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Phase 2 Completed

375 enrolled 24 charts

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01534052 2024-12-06

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Phase 2 Completed

52 enrolled 16 charts

Genitourinary

Prostatic Neoplasms

NCT02799745 2024-12-06

ENACT

Phase 2 Completed

227 enrolled 24 charts

Genitourinary

Prostatic Neoplasms

NCT02124668 2024-11-21

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase 2 Completed

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT04094519 2024-11-20

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Phase 1 Completed

24 enrolled

Genitourinary

Prostatic Neoplasms

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT01995513 2023-09-18

PLATO

Phase 4 Completed

509 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT03569280 2023-07-18

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Phase 1 Completed

16 enrolled

Genitourinary

Prostatic Neoplasms

NCT02438007 2023-03-15

ARMOR3-SV

Phase 3 Terminated

953 enrolled

Genitourinary

Prostatic Neoplasms

NCT05191017 2022-08-05

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Phase 1/2 Withdrawn

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

27 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02711956 2021-11-30

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Completed

75 enrolled 31 charts

Genitourinary

Prostatic Neoplasms

NCT02384382 2020-05-05

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Phase 2 Completed

23 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

MK-5684-004

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

MEVPRO-1

MEVPRO-3

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

AMX-500

AcTFirst

Double-DARE

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

rechARge

PROSPER

CheckMate 9KD

EvoPAR-PR01

SPLASH

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

CONTACT-02

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

ARROW

CDK4i

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

KEYNOTE-641

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

KEYLYNK-010

PRESIDE

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

ENACT

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

PLATO

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

ARMOR3-SV

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)